Literature DB >> 24569953

Laboratory diagnosis of primary immunodeficiencies.

Bradley A Locke1, Trivikram Dasu, James W Verbsky.   

Abstract

Primary immune deficiency disorders represent a highly heterogeneous group of disorders with an increased propensity to infections and other immune complications. A careful history to delineate the pattern of infectious organisms and other complications is important to guide the workup of these patients, but a focused laboratory evaluation is essential to the diagnosis of an underlying primary immunodeficiency. Initial workup of suspected immune deficiencies should include complete blood counts and serologic tests of immunoglobulin levels, vaccine titers, and complement levels, but these tests are often insufficient to make a diagnosis. Recent advancements in the understanding of the immune system have led to the development of novel immunologic assays to aid in the diagnosis of these disorders. Classically utilized to enumerate lymphocyte subsets, flow cytometric-based assays are increasingly utilized to test immune cell function (e.g., neutrophil oxidative burst, NK cytotoxicity), intracellular cytokine production (e.g., TH17 production), cellular signaling pathways (e.g., phosphor-STAT analysis), and protein expression (e.g., BTK, Foxp3). Genetic testing has similarly expanded greatly as more primary immune deficiencies are defined, and the use of mass sequencing technologies is leading to the identification of novel disorders. In order to utilize these complex assays in clinical care, one must have a firm understanding of the immunologic assay, how the results are interpreted, pitfalls in the assays, and how the test affects treatment decisions. This article will provide a systematic approach of the evaluation of a suspected primary immunodeficiency, as well as provide a comprehensive list of testing options and their results in the context of various disease processes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24569953     DOI: 10.1007/s12016-014-8412-4

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  113 in total

Review 1.  Genetic analysis of patients with defects in early B-cell development.

Authors:  Mary Ellen Conley; Arnon Broides; Vivian Hernandez-Trujillo; Vanessa Howard; Hirokazu Kanegane; Toshio Miyawaki; Sheila A Shurtleff
Journal:  Immunol Rev       Date:  2005-02       Impact factor: 12.988

2.  Mechanism of cell-mediated cytotoxicity at the single cell level. IV. Natural killing and antibody-dependent cellular cytotoxicity can be mediated by the same human effector cell as determined by the two-target conjugate assay.

Authors:  T P Bradley; B Bonavida
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

3.  Relative increase of T cells expressing the gamma/delta rather than the alpha/beta receptor in ataxia-telangiectasia.

Authors:  M Carbonari; M Cherchi; R Paganelli; G Giannini; E Galli; C Gaetano; C Papetti; M Fiorilli
Journal:  N Engl J Med       Date:  1990-01-11       Impact factor: 91.245

4.  Multiplexed quantitative real-time PCR to detect 22q11.2 deletion in patients with congenital heart disease.

Authors:  Aoy Tomita-Mitchell; Donna K Mahnke; Joshua M Larson; Sujana Ghanta; Ying Feng; Pippa M Simpson; Ulrich Broeckel; Kelly Duffy; James S Tweddell; William J Grossman; John M Routes; Michael E Mitchell
Journal:  Physiol Genomics       Date:  2010-06-15       Impact factor: 3.107

5.  Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency.

Authors:  Klaus Warnatz; Lukas Bossaller; Ulrich Salzer; Andrea Skrabl-Baumgartner; Wolfgang Schwinger; Mirjam van der Burg; Jacques J M van Dongen; Marzena Orlowska-Volk; Rolf Knoth; Anne Durandy; Ruth Draeger; Michael Schlesier; Hans Hartmut Peter; Bodo Grimbacher
Journal:  Blood       Date:  2005-12-29       Impact factor: 22.113

6.  Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children.

Authors:  Wasu Kamchaisatian; Watcharaphong Wanwatsuntikul; John W Sleasman; Nutthapong Tangsinmankong
Journal:  J Allergy Clin Immunol       Date:  2006-11-07       Impact factor: 10.793

Review 7.  Common variable immunodeficiency.

Authors:  C Cunningham-Rundles
Journal:  Curr Allergy Asthma Rep       Date:  2001-09       Impact factor: 4.806

Review 8.  Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections.

Authors:  Ari J Fried; Francisco A Bonilla
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

9.  Flowcytometric phenotyping of common variable immunodeficiency.

Authors:  Klaus Warnatz; Michael Schlesier
Journal:  Cytometry B Clin Cytom       Date:  2008-09       Impact factor: 3.058

Review 10.  Cell-death signaling and human disease.

Authors:  Frédéric Rieux-Laucat; Alain Fischer; Françoise Le Deist
Journal:  Curr Opin Immunol       Date:  2003-06       Impact factor: 7.486

View more
  10 in total

Review 1.  B-cell receptor repertoire sequencing in patients with primary immunodeficiency: a review.

Authors:  Marie Ghraichy; Jacob D Galson; Dominic F Kelly; Johannes Trück
Journal:  Immunology       Date:  2017-12-18       Impact factor: 7.397

2.  Influenza-specific IgG1+ memory B-cell numbers increase upon booster vaccination in healthy adults but not in patients with predominantly antibody deficiency.

Authors:  Gemma E Hartley; Emily S J Edwards; Julian J Bosco; Samar Ojaimi; Robert G Stirling; Paul U Cameron; Katie Flanagan; Magdalena Plebanski; Philip Mark Hogarth; Robyn E O'Hehir; Menno C van Zelm
Journal:  Clin Transl Immunology       Date:  2020-10-16

Review 3.  Primary Immunodeficiencies: Diseases of Children and Adults - A Review.

Authors:  Aleksandra Lewandowicz-Uszyńska; Gerard Pasternak; Jerzy Świerkot; Katarzyna Bogunia-Kubik
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Overview of Immunodeficiency Disorders.

Authors:  Nikita Raje; Chitra Dinakar
Journal:  Immunol Allergy Clin North Am       Date:  2015-08-25       Impact factor: 3.479

Review 5.  Clinical applications of gene therapy for primary immunodeficiencies.

Authors:  Maria Pia Cicalese; Alessandro Aiuti
Journal:  Hum Gene Ther       Date:  2015-04       Impact factor: 5.695

6.  Evaluating the Stability of RNA-Seq Transcriptome Profiles and Drug-Induced Immune-Related Expression Changes in Whole Blood.

Authors:  John F Bowyer; Karen M Tranter; Joseph P Hanig; Nathaniel M Crabtree; Robert P Schleimer; Nysia I George
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

7.  Combination of lymphocyte number and function in evaluating host immunity.

Authors:  Ying Luo; Yalong Xie; Weijie Zhang; Qun Lin; Guoxing Tang; Shiji Wu; Min Huang; Botao Yin; Jin Huang; Wei Wei; Jing Yu; Hongyan Hou; Liyan Mao; Weiyong Liu; Feng Wang; Ziyong Sun
Journal:  Aging (Albany NY)       Date:  2019-12-20       Impact factor: 5.682

8.  Immune function in newborns with in-utero exposure to anti-TNFα therapy.

Authors:  Batia Weiss; Shomron Ben-Horin; Atar Lev; Efrat Broide; Miri Yavzori; Adi Lahat; Uri Kopylov; Orit Picard; Rami Eliakim; Yulia Ron; Irit Avni-Biron; Anat Yerushalmy-Feler; Amit Assa; Raz Somech; Ariella Bar-Gil Shitrit
Journal:  Front Pediatr       Date:  2022-08-31       Impact factor: 3.569

9.  Recurrent respiratory tract infections in children - analysis of immunological examinations.

Authors:  Agata Raniszewska; Elżbieta Górska; Iwona Kotuła; Anna Stelmaszczyk-Emmel; Katarzyna Popko; Olga Ciepiela
Journal:  Cent Eur J Immunol       Date:  2015-08-03       Impact factor: 2.085

Review 10.  Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data.

Authors:  Irina Kareva; Anup Zutshi; Cristina Vazquez Mateo; Orestis Papasouliotis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-07-30       Impact factor: 2.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.